Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Laura Dumitrescu, Athanasios Papathanasiou, Catalina Coclitu, Afagh Garjani, Nikos Evangelou, Cris S. Constantinescu, Bogdan Ovidiu Popescu & Radu Tanasescu. (2023) An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy 24:4, pages 495-509.
Read now
Read now
Sonda Jallouli, Imen Ben Dhia, Salma Sakka, Chokri Mhiri, Abdelmoneem Yahia, Mohamed Habib Elleuch, Omar Hammouda & Sameh Ghroubi. (2022) Combined effect of gender differences and fatiguing task on postural balance, functional mobility and fall risk in adults with multiple sclerosis: A preliminary study. Neurological Research 44:12, pages 1074-1085.
Read now
Read now
Marzia Fronza, Lorena Lorefice, Jessica Frau & Eleonora Cocco. (2021) An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. Drug Design, Development and Therapy 15, pages 1993-2004.
Read now
Read now
Elisa Baldin & Alessandra Lugaresi. (2020) Ponesimod for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy 21:16, pages 1955-1964.
Read now
Read now
Beatriz Canibaño, Dirk Deleu, Boulenouar Mesraoua, Gayane Melikyan, Faiza Ibrahim & Yolande Hanssens. (2020) Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. Journal of Drug Assessment 9:1, pages 20-36.
Read now
Read now
Claudia Volpi, Ciriana Orabona, Antonio Macchiarulo, Roberta Bianchi, Paolo Puccetti & Ursula Grohmann. (2019) Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Discovery 14:11, pages 1199-1212.
Read now
Read now
Articles from other publishers (21)
Devaraj Basavarajappa, Vivek Gupta, Nitin Chitranshi, Deepa Viswanathan, Veer Gupta, Roshana Vander Wall, Viswanthram Palanivel, Mehdi Mirzaei, Yuyi You, Alexander Klistorner & Stuart L. Graham. (2023) Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury. Molecular Neurobiology 60:12, pages 7222-7237.
Crossref
Crossref
Ruijie Zeng, Rui Jiang, Wentao Huang, Jiaxuan Wang, Lijun Zhang, Yuying Ma, Yanjun Wu, Meijun Meng, Hekui Lan, Qizhou Lian, Felix W. Leung, Weihong Sha & Hao Chen. (2023) Dissecting shared genetic architecture between obesity and multiple sclerosis. eBioMedicine 93, pages 104647.
Crossref
Crossref
Anshul Sharma, Nitin Sharma, Sachin Singh & Kamal Dua. (2023) Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis. Journal of Drug Delivery Science and Technology 81, pages 104220.
Crossref
Crossref
Devaraj Basavarajappa, Vivek Gupta, Nitin Chitranshi, RoshanaVander Wall, Rashi Rajput, Kanishka Pushpitha, Samridhi Sharma, Mehdi Mirzaei, Alexander Klistorner & StuartL Graham. (2023) Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma. Neural Regeneration Research 18:4, pages 840.
Crossref
Crossref
Devaraj Basavarajappa, Vivek Gupta, Roshana Vander Wall, Veer Gupta, Nitin Chitranshi, Seyed Shahab Oddin Mirshahvaladi, Viswanthram Palanivel, Yuyi You, Mehdi Mirzaei, Alexander Klistorner & Stuart L. Graham. (2022)
S1PR1
signaling attenuates apoptosis of retinal ganglion cells via modulation of
cJun
/Bim cascade and Bad phosphorylation in a mouse model of glaucoma
. The FASEB Journal 37:1.
Crossref
Crossref
Pranathi Prasad, Larissa Roth, Rosana-Bristena Ionescu, Cory Willis, Alexandra Nicaise, Grzegorz Krzak, Luca Peruzzotti-Jametti & Stefano Pluchino. 2023. Encyclopedia of Cell Biology. Encyclopedia of Cell Biology
666
686
.
Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, Maria Pia Amato, Tobias Derfuss, Franziska Di Pauli, Ellen Iacobaeus, Marcin Mycko, Hesham Abboud, Anat Achiron, Angelo Bellinvia, Alexey Boyko, Jean-Laurent Casanova, David Clifford, Ruth Dobson, Mauricio F Farez, Massimo Filippi, Kathryn C Fitzgerald, Mattia Fonderico, Riadh Gouider, Yael Hacohen, Kerstin Hellwig, Bernhard Hemmer, Ludwig Kappos, Filipa Ladeira, Christine Lebrun-Frénay, Céline Louapre, Melinda Magyari, Matthias Mehling, Celia Oreja-Guevara, Lekha Pandit, Caroline Papeix, Fredrik Piehl, Emilio Portaccio, Isabel Ruiz-Camps, Krzysztof Selmaj, Steve Simpson-Yap, Aksel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Maria Trojano, Adi Vaknin-Dembinsky, Sandra Vukusic, Brian Weinshenker, Heinz Wiendl, Alexander Winkelmann, María Isabel Zuluaga Rodas, Mar Tintoré & Bruno Stankoff. (2022) The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal 28:9, pages 1424-1456.
Crossref
Crossref
Chen Chaoyang, Dong Xiu, Wei Ran, Ma Lingyun, Zhao Simiao, Li Ruoming, Zhang Enyao, Zhou Ying, Cui Yimin & Liu Zhenming. (2022) Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials. Frontiers in Pharmacology 13.
Crossref
Crossref
Jie Wang, Idan Goren, Bo Yang, Sinan Lin, Jiannan Li, Michael Elias, Claudio Fiocchi & Florian Rieder. (2021) Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 55:3, pages 277-291.
Crossref
Crossref
Łukasz Rzepiński, Piotr Kośliński, Marcin Gackowski, Marcin Koba & Zdzisław Maciejek. (2022) Amino Acid Levels as Potential Biomarkers of Multiple Sclerosis in Elderly Patients: Preliminary Report. Journal of Clinical Neurology 18:5, pages 529.
Crossref
Crossref
Maddalena Sparaco, Giuseppina Miele & Simona Bonavita. (2021) Severe lymphopenia switching from Fingolimod to Siponimod. Neurological Sciences 42:11, pages 4837-4838.
Crossref
Crossref
César Caparó-Zamalloa, Victor Velásquez-Rimachi, Nicanor Mori, Wenzel Ivan Dueñas-Pacheco, Andrely Huerta-Rosario, Chandel Farroñay-García, Roberto A. Molina & Carlos Alva-Díaz. (2021) Clinical Pathway for the Diagnosis and Management of Patients With Relapsing–Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population. Frontiers in Neurology 12.
Crossref
Crossref
Isabella Laura Simone, Carla Tortorella & Alma Ghirelli. (2021) Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies. Frontiers in Neurology 12.
Crossref
Crossref
E. Alvarez, K.V. Nair, M. Gorritz, L. Bartolome, H. Maloney, Y. Ding, T. Golan, R.L. Wade, R. Kumar, W. Su, R. Shah & P. Russo. (2021) Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. Multiple Sclerosis and Related Disorders 50, pages 102858.
Crossref
Crossref
Carlos A. Perez, Andrew Smith & Flavia NelsonCarlos A. Pérez. 2021. Multiple Sclerosis. Multiple Sclerosis
37
44
.
Lesley J. Scott. (2020) Siponimod: A Review in Secondary Progressive Multiple Sclerosis. CNS Drugs 34:11, pages 1191-1200.
Crossref
Crossref
Alessandra Roggeri, Melissa Schepers, Assia Tiane, Ben Rombaut, Lieve van Veggel, Niels Hellings, Jos Prickaerts, Anna Pittaluga & Tim Vanmierlo. (2020) Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation. International Journal of Molecular Sciences 21:20, pages 7537.
Crossref
Crossref
Haibo Mei, Jianlin Han, Sarah White, Daniel J. Graham, Kunisuke Izawa, Tatsunori Sato, Santos Fustero, Nicholas A. Meanwell & Vadim A. Soloshonok. (2020) Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. Chemistry – A European Journal 26:50, pages 11349-11390.
Crossref
Crossref
Michelle Liu & Aniwaa Owusu Obeng. (2019) Siponimod and CYP2C9 Allele Prevalence Among Blacks. The Journal of Clinical Pharmacology 60:4, pages 429-431.
Crossref
Crossref
A. M. Petrov, E. V. Ivashkova & I. D. Stolyarov. (2019) New possibilities for the therapy of secondary progressive multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics 11:4, pages 125-129.
Crossref
Crossref
E. P. Evdoshenko, N. A. Neofidov, K. Z. Bakhtiyarova, M. V. Davydovskaya, E. I. Kairbekova, Yu. M. Kolontareva, N. A. Malkova, M. M. Odinak, E. V. Popova, D. V. Sazonov, I. D. Stolyarov, I. V. Smagina, A. S. Fedyanin, F. A. Habirov, T. I. Khaibullin, N. V. Khachanova, I. A. Shchukin & A. N. Boyko. (2019) The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:10, pages 110.
Crossref
Crossref